Erasca, Inc. (ERAS)
NASDAQ · Manufacturing · Pharmaceutical preparations
ERAS price, last 12 months
Key stats
- Previous close
- $13.76
- Open
- $14.07
- Day range
- $13.72 – $14.69
- 52-week range
- $2.75 – $24.28
- Volume
- 4.8M
- Avg volume (20 days)
- 5.7M
- Market cap
- $5.5B
Performance
Technicals and fundamentals
About Erasca, Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.5B